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  Summary 
 
 
Breast cancer is the most common and most lethal cancer in women worldwide, 
affecting 1.38 million women in 2008 and being responsible for 23% of all cancers 
cases in this gender, with an associated mortality rate of 13.7% (460.000 deaths). 
There are currently several treatment strategies, but a large number of cases stands 
without adequate therapy or develop resistance to it. Deregulation of the "homeobox" 
gene HOXB13, crucial in cell division and differentiation, has been associated with 
several cancer models. This gene is known to be overexpressed in breast cancer cells, 
associated with an increased tumoral proliferation and a worse clinical outcome, 
suggesting an oncogenic role for this gene. Furthermore, it has been shown that high 
HOXB13 expression is associated with resistance to tamoxifen therapy, through a not 
well studied mechanisms, related with estrogen receptors suppression and induction of 
alternative pathways.  
The main goal of this master thesis was to try to understand better the role and 
relevance of HOXB13 in breast cancer. More specifically, one goal was to find out if 
germline HOXB13 mutations occur in familial breast cancer (some of which having also 
prostate cancer), negative for mutations in BRCA1 or BRCA2. Additionally, the 
relevance of copy number changes and amplification for HOXB13 expression in breast 
carcinomas was evaluated. Finally, the findings were correlated with clinico-
pathological parameters. 
To address these aims, DNA from 95 peripheral blood samples was extracted 
and amplified and both HOXB13 exons were sequenced to verify if there were any 
germline mutations. Next, to quantify the HOXB13 expression levels in breast cancer 
cases with and without 17q21 gain (CGH available data), a qRT-PCR was done in 84 
samples of cDNA, adjusting the values for the endogenous control gene, GUSB. To 
directly evaluate copy number changes in HOXB13, the cytogenetic technique FISH 
was performed, using a probe that was able to cover our gene of interest (located in 
17q21) and a control probe to the centromeric region of chromosome 17.  
No deleterious germline mutations were found in any of the 95 cases of familial 
breast cancer, wildtype for mutations in the BRCA1/2 genes. Furthermore, a statistical 
association was found between the 17q21 status, measured by CGH, and the 
expression levels of HOXB13. By FISH analysis, although HOXB13 amplifications were 
found in 8 tumor samples, no significant association was found between copy number 
changes and HOXB13 expression. However, there was a significant association 
vi 
 
between higher levels of HOXB13 expression in breast carcinomas with HOXB13 
amplifications, when compared with breast carcinomas with and without 17q21 gain, by 
CGH, but no HOXB13 amplification. Concerning clinico-pathological associations, we 
found no prognostic or predictive value of HOXB13 expression in the limited series of 
breast cancer patients analyzed but there was indeed an association with tumor grade 
and HER2 status. 
In conclusion, no evidence was found that the HOXB13 gene is a significant 
contributor to inherited predisposition to familial breast cancer in Portugal, both 
regarding the recurrent G84E mutation or any other. Furthermore, mean HOXB13 
expression is higher in breast carcinomas with 17q21 gain and also in tumors with 
HOXB13 amplification, especially when compared with tumors without 17q21 gain, but 
and no HOXB13 amplification, this difference suggests that genetic copy number gain, 
can be the main mechanism for HOXB13 overexpression in breast cancer.  
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  Resumo 
 
 
O cancro da mama é o mais comum e mais letal na mulher mundialmente, tendo 
afectado 1.38 milhões de mulheres em 2008 e sendo responsável por 23% de todos 
os casos de cancro neste género, com uma taxa de mortalidade associada de 13.7% 
(460.000 mortes). Actualmente existem várias estratégias de tratamento, mas um 
elevado número de casos permanece sem uma terapêutica adequada, ou desenvolve 
uma resistência à mesma. A desregulação do gene "homeobox" HOXB13, crucial na 
divisão e diferenciação celular, tem sido associada a vários modelos de cancro. Sabe-
se que este gene está sobrexpresso nas células de cancro da mama, associado a um 
aumento na proliferação tumoral e a uma maior agressividade clínica, sugerindo assim 
um papel oncogénico para este gene. Foi também já provado, que a elevada 
expressão de HOXB13 está associada com a resistência ao tamoxifen, por 
mecanismos ainda pouco estudados, relacionados com a supressão dos receptores de 
estrogénio e indução de vias alternativas.  
O maior objectivo desta tese de mestrado foi tentar perceber melhor o papel e 
relevância do HOXB13 no cancro da mama. Mais especificamente, um dos objectivos 
foi saber se mutações germinativas ocorriam em cancro da mama familiar (alguns dos 
quais com casos de cancro da próstata) negativos para mutações no BRCA1 e 
BRCA2. Adicionalmente, avaliar a relevância de alterações no número de cópias e 
amplificações do HOXB13, para a sua expressão em carcinomas da mama. Por 
último, os resultados foram correlacionados com os parâmetros clinico-patológicos. 
Para realizar estes objectivos, extraiu-se e amplificou-se o DNA de 95 amostras 
de sangue periférico e sequenciaram-se ambos os exões do HOXB13, para verificar 
se havia mutações germinativas. Seguidamente, para quantificar os níveis de 
expressão do HOXB13 em casos com cancro da mama, com e sem ganho do 17q21 
(dados disponíveis de CGH), fez-se qRT-PCR em 84 amostras de cDNA, ajustando os 
dados para o gene de controlo endógeno, GUSB. Para avaliar directamente alterações 
no número de cópias do HOXB13, foi feita a técnica citogenética de FISH, usando uma 
sonda que capaz de cobrir o nosso gene de interesse (localizado no 17q21) e uma 
sonda controlo para a região centromérica do cromossoma 17.  
Não foram encontradas mutações germinativas no HOXB13 nos 95 casos de 
cancro de mama familiar, negativos para mutações no BRCA1/2. Foi encontrada uma 
associação estatisticamente significativa entre o ganho da região 17q21, dados 
fornecidos por CGH, e o nível de expressão do HOXB13. Por análise de FISH, apesar 
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de terem sido descobertas amplificações do HOXB13 em 8 amostras de tumor, não foi 
encontrada nenhuma associação significativa entre as alterações no seu número de 
cópias e a expressão do mesmo. No entanto, verificou-se novamente uma associação 
positiva entre os valores de expressão do HOXB13 mais elevados e carcinomas da 
mama com amplificações do HOXB13, especialmente quando comparados com 
carcinomas da mama sem ganho do 17q21 por CGH, assim como sem amplificação 
deste gene. No que diz respeito às associações clinico-patológicas, não encontramos 
qualquer valor preditivo ou de prognóstico nos níveis de expressão do HOXB13, na 
limitada série estudada, apenas uma associação com o grau do tumor e o receptor 
HER2.  
Concluindo, não foi encontrada nenhuma evidência de que o gene HOXB13 
contribua significativamente para uma predisposição hereditária para cancro da mama 
familiar em Portugal, quer no que diz respeito à mutação recorrente G84E, ou qualquer 
outra. Os níveis médios de HOXB13 revelaram ser mais elevados em carcinomas da 
mama com ganho da região 17q21 assim como nos casos com amplificação deste 
gene, especialmente quando comparados com tumores sem ganho do 17q21 e sem 
amplificação do HOXB13. Esta diferença estatisticamente significativa, sugere então o 
aumento do número de cópias como um mecanismo responsável para a 
sobrexpressão do HOXB13 em cancro da mama. 
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  I. Introduction 
 
1. Breast cancer 
 
1.1  Epidemiology 
 
Cancer continues to increase its numbers every year across the world, in part 
because of the aging of the population and its continuous growth, alongside with an 
augmented adoption of cancer-causing behaviors. About 12.7 million cancer cases and 
7.6 million cancer deaths are estimated to have occurred in 2008 [1], but there has also 
been an improvement in survival rates [2]. 
Breast cancer is the most common and remains the most lethal cancer in women 
worldwide, being responsible for almost 23% (1.38 million) of the cancers affecting 
women and with an associated mortality of 13.7%, corresponding to 460,000 deaths 
(2008) [1]. About 20% of breast cancers occur among women aged younger than 50 
years, while 40% occur among women aged 65 years and older [2]. Mortality rates are 
also highest in young women (<35 years), associated with a more aggressive disease, 
and in the very old (>75 years) because they are not treated aggressively [3]. It is 
estimated that a million women will develop breast cancer each year [4]. Breast 
carcinoma in men represents approximately 1% of all breast cancers and 1% of all 
malignancies in men, but the incidence of male breast cancer appears to be increasing 
[5]. 
About half of the breast cancer cases and 60% of the deaths are estimated to 
occur in economically developing countries, associated with a higher prevalence of the 
already known risk factors for the disease [1], which will be discussed ahead. The 
highest incidence rates of breast cancer are observed in Northern and Western 
Europe, North America, Australia, New Zealand and in the southern countries of South 
America; intermediate incidence rates appears in South America, the Caribbean, and 
Northern Africa; and low incidence rates are seen in sub-Saharan Africa and Asia [2] 
[Figure 1.1]. 
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In Europe, approximately 426,000 (28.2%) women were diagnosed with the 
disease in 2008 and 30.3% of them actually died because of it, representing the 
second cause of cancer related deaths (17%) [6] [Figure 1.2]. Considering the 
European Union (EU-27), in the same year, breast cancer represented 13.5% of all 
cancer cases in women, ranking the leading cause of cancer death (89,801; 16.6%), 
followed by the lung (71,100, 13.5%) and colorectal (69,000, 12.8%) cancers [7,8]. 
 
 
 
 
 
 
 
 
 
Figure 1.1 - The global burden of breast cancer in 2002: age-standardized incidence rates per 
100.000 [adapted from: Li (2010)].     
   
Figure 1.1 – The global burden of breast cancer in 2002: age-standardized incidence rates per 
100.000 [adapted from: Li (2010)].     
 
Figure 1.2 - Estimated age-standardized 
incidence and mortality rates in 
European women [adapted from: 
http://globocan.iarc.fr]. 
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 A fall in breast cancer mortality rates, in most European and other developed 
countries in the 1990s, was reported by several studies. These declines have been 
attributed to the combined effect of changes in reproductive factors, earlier detection 
and improving treatment [9], but it was observed mainly in young women. Because of 
the aging of the European population, the number of deaths from breast cancer is still 
disturbingly high (130,000 in 2004, 132,000 in 2006 and 129,000 in 2008). The 
introduction of organized mammography screening programs throughout Europe, has 
lead to a reduction in breast cancer mortality, being the short-term consequence, an 
increased incidence [10]. 
In Portugal, breast cancer is the most incident type of cancer, both considering 
only women (27.6%) or both sexes (12.3%). It is the cancer with higher associated 
mortality if we consider only female gender (16%), being responsible for 1,537 deaths 
in 2008 in this country [6]. 
 
1.2  Etiology and risk factors 
 
          
         Various risk factors for breast cancer have been recognized through the years, 
some with more impact than others. Among them, it is known that besides genetic and 
lifestyle variables, reproductive factors are strongly involved in the etiology of breast 
cancer, mainly for being a hormone dependent malignancy and its risk associated with 
the endogenous level of estrogens [11] [Table 1.1]. 
 
Gender: Is the greatest risk factor. Breast cancer is 100 times more frequent in 
women than men [12]. 
 
 Age: The incidence increases with age, doubling about every 10 years until 
menopause, when the rate of increase dramatically slows. By the ages 75 to 80 the 
curve actually decreases [13]. 
 
Race/ethnicity: Incidence rates are higher in non-Hispanic white woman 
compared to women with African origins for most age groups. However, African women 
have a higher incidence rate before 40 years of age and are more likely to die from 
breast cancer at every age. Incidence and death rates are lower among women of 
other racial and ethnic groups (Hispanic/Latina; Indian; Asian) [10]. 
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Age at menarche and menopause: Women who start menstruating early in life 
or who have a late menopause have an increased risk of developing breast cancer. 
The risk decreases by about 15% for each year of delay in age at menarche and 
increases by 3% for each year of delay in age at menopause [11]. 
 
Age at first pregnancy: Nulliparity and late age at first birth increase the lifetime 
incidence of breast cancer. The highest risk group are those who have a first child after 
the age of 35. These women appear to be at even higher risk than nulliparity women 
[14]. 
 
Family history: Only 5% to 10% of breast cancers are considered hereditary. 
Mutations in the BRCA1 and BRCA2 genes account for an estimated 80% of the 
hereditary cases and confer a 45% to 80% lifetime risk of developing this type of 
cancer [15]. Familial breast cancer is considered a risk if a first degree relative develops 
this malignancy before menopause, if it affected both breasts or if it occurred in 
conjunction with ovarian cancer [16]. 
 
Previous benign breast disease: Women with severe atypical epithelial 
hyperplasia have a four to five times higher risk of developing breast cancer than 
women who do not have any proliferative changes [12]. 
 
Radiation: A doubling of risk of breast cancer was observed among teenage girls 
exposed to radiation. Ionizing radiation also increases risk later in life, particularly when 
exposure is during rapid breast formation (prepubertal years of 10 to 14) [17]. 
 
Lifestyle: Although there is a close correlation between incidence of breast 
cancer and dietary fat intake, the true relationship does not appear particularly 
consistent [18]. Obesity is associated with a two fold increase in the risk in 
postmenopausal women whereas among premenopausal women is associated with a 
reduced incidence [19]. The relation with smoking status is inconsistent, but recent 
evidence has suggested a potential role of active smoking in breast cancer 
development, particularly with long-term heavy smoking and smoking initiation at an 
early age [20]. Alcohol has been linked to increased blood levels of estrogen, thus 
increasing the risk of breast cancer development [21]. 
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Oral contraceptive: When women are taking oral contraceptives and for the 10 
years after stop using these agents, there is a small increase in the relative risk of 
developing breast cancer. Duration of use, age at first use, dose and type of hormone 
within the contraceptives appear to have no significant effect on breast cancer risk. 
Women who begin use before the age of 20 appear to have a higher relative risk than 
women who begin oral contraceptive use at an older age [22]. 
 
Hormone replacement therapy (HRT): Among current users of HRT and for 
those who have previously used this therapy during a long term, the relative risk of 
developing breast cancer increases by a factor of 1,023 for each year of use. The risk 
of breast cancer appears higher with combined estrogen and progesterone therapy. 
Moreover, HRT increases breast density and reduces the sensitivity and specificity of 
breast screening [23]. 
 
 
 
RELATIVE 
RISK 
HIGH RISK GROUP 
 
 
 
>4 
Age (>65 vs <65 years, although risk increases across all ages until age 
80) 
Biopsy-confirmed atypical hyperplasia 
Certain inherited genetic mutations for breast cancer (BRCA1 and/or 
BRCA2) 
Mammographically dense breasts 
Personal history of breast cancer 
2.1-4.0 
High endogenous estrogen or testosterone levels 
High bone density (postmenopausal) 
High-dose radiation to chest 
Two first-degree relatives with breast cancer 
1.1-2.0 
Alcohol consumption 
Ashkenazi Jewish heritage 
High socioeconomic status 
Late age at first full-term pregnancy (>30 years) 
Early menarche (<12 years) and late menopause (>55 years) 
Never breastfed a child 
No full-term pregnancies 
Obesity (postmenopausal)/adult weight gain and  height (tall) 
One first-degree relative with breast cancer 
Personal history of endometrium, ovary, or colon cancer 
Recent and long-term use of menopausal hormone therapy containing 
estrogen and progesterone 
Recent oral contraceptive use 
Table 1.1 - Factors that increase the risk for breast cancer development in women [adapted from: 
DeSantis et al (2012)]. 
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1.3 Anatomy and pathology 
 
Breast starts developing between the ages of 9-14 years for most women, when 
hormonal changes associated with puberty begin to occur. The breast is the tissue 
overlying the chest (pectoral) muscles. Women's breasts are made of specialized 
tissue that produces milk (glandular tissue) as well as fatty tissue. The amount of fat 
determines the size of the breast [24]. During pregnancy the breasts grow further and 
this growth is much more uniform than that at adolescence. The amount of milk-
producing tissue is essentially the same in all women [25]. 
Each breast has 15 to 20 sections called lobes. Each lobe has many smaller 
lobules where milk is produced. These structures are linked by thin tubes called ducts 
that lead to the nipple in the center of a dark area of skin called the areola. Fat fills the 
spaces between lobules and ducts, and connective tissue and ligaments provide 
support to the breast and give it its shape. The breast also contains blood vessels, 
lymph vessels and lymph nodes [Figure 1.3].  The mammary glands exist in the male 
as well as in the female, but in the former, only in the rudimentary state [24].                        
 
 
 
 
Among benign lesions related to cancer of the breast, inflammatory lesions, 
fibrocystic, proliferative and granulomatous diseases can be distinguished [12] [Table 
1.2]. 
 
Figure 1.3 - Anatomy of the female breast. Front and side view [adapted from: http:// 
www.yalemedicalgroup.org].     
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Ninety-five percent of the breast cancers are carcinomas, which arise from breast 
epithelial elements. Breast cancers are divided into two major types, in situ carcinomas 
and invasive (or infiltrating) carcinomas. The in situ carcinomas may arise in either 
ductal (DCIS) or lobular epithelium (LCIS), but remain confined, with no invasion of the 
underlying basement membrane. As would be expected with such localized and 
confined malignancy, there is little potential for metastases [12]. When there is 
extension of the malignancy beyond the basement membrane, then the malignancy is 
considered invasive and consists of several histological subtypes: invasive ductal not 
otherwise specified (76%), invasive lobular (8%), mixed ductal/lobular (7%), mucinous 
(2.4%), tubular (1.5%), medullary (1.2%) and papillary (1%) [Figure 1.4]. Other 
subtypes including cribriform carcinoma, metaplastic breast cancer and invasive 
micropapillary breast cancer, account for fewer than 5% of the cases. The potential for 
metastases and ultimately death occurs in invasive disease [26].    
There are two major "arms" in the multi-pathway model of breast cancer 
progression: one comprising well differentiated DCIS that progresses to grade I 
invasive ductal carcinoma (IDC) and the second comprising poorly differentiated DCIS 
that progresses to grade III IDC [27]. About 85% of all intraductal cancers, often with 
less than 1 centimeter, are detected by the appearance of clustered microcalcifications 
on mammography and their morphology is important to differentiate between benign 
and malignant calcification [28]. Also interesting is the comedo-type DCIS, which is 
more malignant than other types of DCIS and is probably between DCIS and invasive 
cancer [29].  
 
Inflammatory 
lesions 
Fibrocystic 
disease 
Proliferative 
diseases 
Granulomatous 
disease 
Acute mastitis Apocrine metaplasia 
Ductal/Lobular 
hyperplasia 
Foreign bodies 
Fat necrosis Epithelial metaplasia 
Sclerosing 
adenosis 
Infections 
Mammary duct ectasia 
Fibrosis and cyst 
formation 
Radial scar Systemic conditions 
Other granulomatous 
lesions 
----- ----- ---- 
Table 1.2 - Benign lesions of the breast [adapted from: Richie et al  (2003)]. 
8 
 
Recently a pleomorphic variant of lobular carcinoma (PLC) has been described, 
in which cells show the typical discohesiveness of lobular neoplasia, but they are of 
high grade and show features of apocrine differentiation [27]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4 Screening, detection and staging 
 
The underlying premise for breast cancer screening is that it allows the detection 
of small tumors that are more likely to be at an early stage of the disease, have a better 
prognosis, and have a more successful treatment. Women at increased risk of breast 
cancer might benefit from additional screening strategies, beyond those offered to 
women of average risk [30] [Table 1.3]. 
Figure 1.4 - Histological based tumor subtyping classification. A- Invasive lobular carcinoma; B- 
Mucinous carcinoma; C- Tubular carcinoma; D- Medullary carcinoma; E- Papillary carcinoma; F- 
Cribriform carcinoma [adapted from: http://www.breastpathology.info]. 
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    The most common symptom of breast cancer is a new mass [31] and several 
methods can be used to find out if the disease is present: the "triple diagnosis", which 
includes clinical examination, mammography and/or ultrasonography, and fine-needle 
aspiration for cytology or core needle biopsy for histopathological examination [32]. 
Widespread use of screening mammograms has increased the number of breast 
cancers found before they cause any symptoms, despite the window of opportunity 
between mammogram detection and possible palpation due to augmented breast 
Organization Risk Group BSE CBE MMG MRI 
 ≥1.7% at ≥35 y Encouraged 
Every 6–12 
m 
Annual (35 
yr)  
NA 
National 
Comprehensive 
Cancer Network 
Strong family 
history 
Encouraged 
Every 6–12 
m 
Annual 
(varies) 
NA 
 Genetic high risk 
Monthly 
(18 yr) 
Every 6 mo 
(25 yr) 
Annual (25 
yr) 
Annual (25 
yr) 
Cancer Genetics 
Studies 
Consortium 
BRCA mutation 
Monthly 
(18 yr) 
Every 6 mo 
(20–25 yr) 
Annual (20–
25 yr) 
NA 
National Institute 
for Health 
and Clinical 
Excellence 
>8% (30–39 yr) 
or >20% (40–49 
yr) or 
>12% (40–49 yr) 
plus dense breast 
tissue or BRCA 
mutation or p53 
NA NA 
Annual digital 
(40 yr) 
Annual (30 
yr;  
20 yr for 
p53) 
American Cancer 
Society 
BRCA mutation; 
untested close 
relative of carrier; 
lifetime risk 
of at least 20–
25%; chest 
radiation at age 
10–30; Li–
Fraumeni 
and close relative 
with breast 
cancer; Cowden 
and close relative 
with breast 
cancer 
Annual NA NA Annual 
Table 1.3 - Recommended guidelines for breast cancer screening for women with a hereditary risk. 
[adapted from: Robson & Offit (2007)]. 
BSE- breast self-examination, CBE- clinician-performed breast examination, MMG- mammography, 
MRI- magnetic resonance imaging and NA- not available. 
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tumor density or size, being very small. In fact, more than 90% of breast cancer 
diagnoses are made early in the disease [33].  
Still, some breast cancers are not found by mammogram, either because the test 
was not well done or because, even under ideal conditions, mammograms do not find 
every breast cancer [34]. Some MRI can detect invisible tumors for mammography 
screening [Figure 1.5]. This type of technique is recommended as a screening tool for 
women who have a 20% or greater increased lifetime risk of breast cancer [35]. 
 
 
 
 
 
 
 
 
 
 
 
After breast cancer has been diagnosed, tests are done to find out if cancer cells 
have spread within the breast or to other parts of the body [36]. 
The TNM classification for staging breast cancer [Table 1.4] consists in three 
main evaluations: 
 
The tumor size (T) - 
TX - Primary tumor cannot be assessed; 
T0 - No evidence of primary tumor; 
Tis - Carcinoma in situ [Figure 1.6]; 
T1 - Tumor with 2 cm or less in greatest dimension; 
T2 - Tumor with more than 2 cm but not more than 5 cm in greatest dimension; 
T3 - Tumor with more than 5 cm in greatest dimension; 
T4 - Tumor of any size with direct extension: (a) chest wall or (b) skin [31]. 
Figure 1.5 - Mammographically (MMG) occult breast cancer detected in the carrier of a BRCA2 
mutation on magnetic resonance imaging (MRI) [adapted from: Robson (2007)]. 
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The regional lymph node involvement (N) - 
NX - Regional lymph nodes cannot be assessed; 
N0 - No regional lymph node metastasis; 
N1 - Metastasis to movable ipsilateral axillary lymph node(s); 
N2 - Metastasis to ipsilateral lymph node(s) fixed or matted, or in clinically apparent 
ipsilateral internal mammary nodes in the absence of evident axillary node metastasis; 
N3 - Metastasis to ipsilateral infraclavicular lymph node(s) with or without clinically 
evident axillary lymph nodes, or in clinically apparent ipsilateral internal mammary  
lymph node(s) and in the presence of clinically evident axillary lymph node metastases, 
or metastasis in ipsilateral supraclavicular lymph nodes with or without axillary or 
internal mammary nodal involvement [31]. 
 
Distant metastasis (M) -          
MX - Distant metastasis cannot be assessed; 
M0 - No distant metastasis; 
M1 - Distant metastasis [31] [Figure 1.7]. 
 
 
 
Figure 1.6 - Ductal and lobular carcinoma in situ  [adapted from: http://www.cancer.gov].  
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At initial diagnosis, over 50% of the breast cancers are stages 0 or I, and 75% 
are stage 0, I or II. The quantity of lymph node involvement has a profound impact on 
survival. Stage IIA cancer with only 1 involved lymph node has a 10 year disease free 
survival of 71% and a 20 year disease free survival of 66%. If 2 to 4 lymph nodes are 
involved, the 10 year disease free survival decreases to 62% and the 20 year disease 
free survival to 56% [37]. The 5 year relative survival rate for women diagnosed with 
localized breast cancer is 98.6%, but it declines to 83.8% for regional stage and to 
23.3% for distant stage [2]. The overall 5 year relative survival rate for female breast 
cancer patients, has improved significantly in the last decades, from 75.1% between 
1975 to 1977, to 90.0% for 2001 through 2007 [38].  
 
Stage groupings 
Stage 0 - Tis N0 M0 
Stage I - T1 N0 M0 
Stage IIA - T0 N1 M0; T1 N1 M0; T2 N0 M0 
Stage IIB - T2 N1M0; T3 N0 M0 
Stage IIIA - T0 N2 M0; T1 N2 M0; T2 N2 M0; T3 N1 M0; T3 N2 M0 
Stage IIIB - T4 Any N M0 
Stage IIIC - Any T N3 M0 
Stage IV - Any T any N M1 
Figure 1.7 - Stage IV of breast cancer 
(any T; any N;M1) [adapted from: 
http://www.cancer.gov]. 
 
Table 1.4 - Breast cancer TNM staging groups [adapted from: Kalogerakos et al (2008)]. 
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In addition to stage, factors that influence prognosis and survival include: tumor 
grade - well differentiated tumors present better prognosis; histological type - specified 
types (tubular, mucinous, medullar, etc) have better prognosis than not specified types 
(IDC-NOS); proliferation index - high levels of proliferation (mitotic index) are 
associated with worse prognosis; ploidy - aneuploid tumors have worse prognosis; 
hormone receptor status - tumors that are positive for this receptors have better 
prognosis; human epidermal growth factor receptor (HER2) status - overexpression of 
this gene is associated with a worse prognosis, but it can be used as a therapeutic 
target for Herceptin [2]. Actually, the 5 year survival rate for Triple Negative (ER-; PR-; 
HER2-) breast cancer is about 77% [39].                         
 
1.5  Treatment strategies 
 
Improvement in breast cancer treatment has undoubtedly increased the long-
term survival of patients as reflected by the increased overall survival, across all breast 
cancer stages [31]. Nowadays, personalized medicine also seeks to offer the proper 
treatment to the right person, at the right time. 
 
 1.5.1  Surgical therapy  
 Surgical treatment for breast cancer involves Breast Conserving Surgery (BCS) 
or mastectomy. When BCS is appropriately used for localized or regional cancers, 
long-term survival is the same as with mastectomy [40]. However, some patients 
require mastectomy for clinical conditions, and others elect it because of personal 
reasons [2]. Mastectomy is also recommended if the risk of recurrence, over the next 5 
to 10 years is >10% to 15%, even after surgery and radiation [41,31]. Regardless of the 
method used, an axillary lymph node dissection is always needed because is the most 
important prognostic factor for recurrence and survival [42].  
The following graphic shows treatment patterns among women diagnosed with 
early or late stage breast cancer, concerning surgery and adjuvant options [19] [Figure 
1.8]. 
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1.5.2  Radiation therapy  
 Usually is done after the surgery and is known to substantially reduce the risk of 
locoregional recurrence by 19% after 5 years, and improves breast cancer mortality by 
5.4% after 15 years [43]. Doses of 45 to 50 Gray (Gy) are typically given to the whole 
breast in daily fractions over a 5-week period, followed by a tumor boost over 1 to 2 
weeks [44]. There are side effects but adjuvant radiation therapy after mastectomy is 
recommended to patients with tumors >5 centimeters regardless of lymph node status 
and those who have four or more positive lymph nodes [45]. If systemic chemotherapy 
is indicated, it will usually be completed before the initiation of radiotherapy [46]. 
 
 1.5.3  Chemotherapy 
 Adjuvant chemotherapy shows results in terms of delayed tumor recurrence [47]. 
In most cases, chemotherapy is more effective when combinations of more than one 
drug is used. The original regimen was CMF (cytoxan, methotrexate, fluorouracil), but 
now many are being used, and it is not clear that any single combination is clearly the 
best. Some of the most used groups of drugs are the anthracyclines and the taxanes, 
but due to increased toxicity, taxanes are only recommended for patients at 
moderate/high risk of recurrence (node positive, HER2 positive, young age) [31].        
 
1.5.4  Hormone therapy  
A lot of research has been carried out on the mechanism of action of steroid 
hormone receptors, which has helped to identify potential molecular targets, that could 
be used to prevent or treat breast cancer. However, there is still ongoing search for 
drugs with maximal benefits and minimal undesirable effects. Briefly, they can be used 
to reduce the production of hormones or block them from working [48]. Some of the 
most important groups are: 
Figure 1.8 - Female breast cancer treatment patterns by stage [adapted from: Siegel et al (2008)]. 
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Selective Estrogen Receptor Modulators: This group of drugs act as receptor 
binding competitors of estrogen and block their effects. The most common and 
successfully used member of this group is tamoxifen, which is a non-steroidal anti-
estrogen that antagonizes the effects of estrogens [Figure 1.9]. It is used in both 
prevention and treatment of breast cancers that are responsive to estrogen, although 
sometimes tumors develop resistance to this type of treatment [49].  
 
 
 
 
 
 
 
 
 
Selective Estrogen Receptor Down-Regulators: These are anti-estrogens with no 
agonist activity and are more potent than SERMs. One of the most widely used 
members is fulvestrant, which is a steroidal anti-estrogen that has a 100-fold higher 
affinity to the ER than tamoxifen, with no agonist activity in the uterus [50]. 
 
Aromatase Inhibitors: These agents are superior to tamoxifen in both efficacy and 
toxicity, and have the potential to reduce receptor-negative tumors by synergy with 
COX-2 inhibitors [51]. Aromatase inhibitors block the production of estrogens from 
androgens, which is the main pathway of estrogen production in post-menopausal and 
non-pregnant women, as well as from other tissues throughout the body [52].    
 
 1.5.5  Targeted therapy 
 It is a type of treatment that uses drugs or other substances to identify and attack 
specific cancer cells, without harming normal cells. Monoclonal antibodies and tyrosine 
kinase inhibitors are two types of targeted therapies used in the treatment of breast 
cancer [53]. 
The most known agent in this group is Herceptin (trastuzumab), a monoclonal 
antibody against the external domain of HER2 receptor, overexpressed in around 20% 
Figure 1.9 - Tamoxifen action on estrogen receptors [adapted from: http://www.cancer.gov]. 
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of the breast cancers [54]. In some studies, trastuzumab showed a reduction of 
mortality, recurrence and metastases rates compared to patients never treated with the 
drug [55]. However, not all patients benefit from this drug, around 15% of women 
relapse after trastuzumab-based therapy [56]. Other used agents can be: Perjeta 
(pertuzumab), a humanized monoclonal antibody that binds to the extracellular domain 
II of HER2. Its mechanism is complementary to trastuzumab, inhibiting ligand-
dependent HER2-HER3 dimerization [57]; Tyberb (lapatinib) competes with adenosine 
triphosphate for its binding site, on the tyrosine kinase domain of HER2 and EGFR 
inactive form, being a dual inhibitor useful for a wider range of patients [58]; Avastin 
(bevacizumab) is a humanized monoclonal antibody, designed to block vascular 
endothelial growth factor A (VEGF-A). It can be used for the treatment of metastatic 
breast cancer [59]; Afinitor (everolimus) is a mTOR inhibitor that works against 
hormone-receptor-positive breast cancers that have stopped responding to other 
drugs, by stopping the cancer cells from getting the energy they need [60]; PARP 
inhibitors are a type of targeted therapy being studied for the treatment of triple-
negative breast cancer, because the absence of poly(ADP-ribose) polymerase leads to 
spontaneous single strand breaks, which are usually repaired by homologous 
recombination. Individuals with a defect in BRCA1/2 are extremely sensitive to these 
inhibitors [61]. 
 
 
2. Genetic and molecular alterations in breast cancer 
 
2.1 Molecular classification of breast cancer subtypes 
 
Breast cancer is a heterogeneous group of several subtype entities, displaying 
distinct biological and clinical differences. Besides histopathological assessment and 
the hormonal receptors status, comprehensive molecular profiling using microarray-
based technology has resulted in useful clinical information [62]. Five distinct intrinsic 
subtypes have been identified, based solely on gene expression, with distinct 
prognostic signatures: luminal A, luminal B, HER2 overexpressing, basal-like and 
normal breast tissue-like [63] [Figure 1.10]. Recent studies have also identified a new 
intrinsic subtype known as Claudin-low or mesenchymal-like [7]. 
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The emergence of next-generation sequencing has now allowed the 
characterization of the mutational landscape of this disease. Based on significant 
genetic diversity due to both inherited genetic variation and acquired genomic 
aberrations, that contributes to cancer initiation and progression [64], Dawson et al [62] 
created a new classification consisting in ten integrative clusters, with distinct clinical 
features and outcomes. 
The 70-gene signature MammaPrint and the 21-gene signature OncoType, are 
being used in selected patients, to obtain more accurate prognostic information [7]. 
 
2.2 Multistep carcinogenesis pathway of breast cancer 
 
Breast cancer emerges by a multistep transformation of normal cells via 
hyperplasia, premalignant change and in situ carcinoma [Figure 1.11]. The 
understanding of the molecular role in cancer development, progression and 
metastases, is important for new prevention and treatment methods, but in breast 
cancer it is not easy to establish a single and definitive carcinogenesis model. Breast 
cancer is a hormone related type of cancer, associated with a carcinogenesis 
mechanism in which hormones (endogenous and exogenous) drive cell proliferation, 
along the progression pathway, increasing the number of cell divisions and the chance 
for random genetic errors [65].   
It was already demonstrated that tumor development involves the accumulation 
of various genetic alterations, including amplification and activating mutation of 
oncogenes and inactivating mutation or loss of tumor suppressor genes. This loss of 
function can occur through sequential gene mutation events (somatic alterations), or 
Figure 1.10 - Hierarchical 
clustering of 20 breast tumor 
tissues analyzed by arrays 
using 526 mapped intrinsic 
genes [adapted from: Sorlie et 
al  (2006)]. 
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through a single mutation event of a remaining normal copy when there is a germline 
mutation [66]. 
 
 
 
 
 
 
 
 
 
 
The evolution of breast cancer and the interactions of genetic predisposing 
factors with somatic changes are summarized in Figure 1.12. In breast cancer, 
oncogene amplification is a common mechanism, but only few oncogenes seem to be 
essential for cancer development. These include three chromosome locations, 8q24 (c-
myc), 11q13 (int2, BCL1, EMS1, FGF3/4, CCND1), and 17q12 (c-erbB2 or HER2). 
Oncogene amplification, however, is not an early event in the multistep carcinogenesis 
pathway of breast cancer [4]. 
A consistently mutated tumor suppressor gene, in sporadic breast cancer, is 
TP53, with point mutations in approximately 22-34% of the cases [67]. Loss of 
heterozygosity incidences higher than 10%, have been observed in familial and 
sporadic breast cancer, with frequencies ranging between 20% and 79%. As seen for 
oncogene amplification and breast cancer development, some loci seem to be 
pathognomonic for the development or progression of a specific histological subtype 
[68].  
Some studies defend that more than any other clinico-pathological parameter, the 
tumor grade strongly reflects the extent, complexity and type of genomic aberrations. 
For instance, grade I and tubular breast carcinomas, show a low number of genomic 
alterations with highly recurrent losses of 16q, whereas grade III breast carcinomas 
show complex genotypes frequently harboring loss of 11q, 14q, 8p, 13q; gain of 17q, 
8q, 5p; and high level gains (amplifications) on 17q12, 17q22-24, 6q22, 8q22, 11q13 
and 20q13. A lower number of genetic changes are found in ILCs relative to IDC [27]. 
Figure 1.11 - Schematic representation of some genomic events associated with breast cancer 
progression [adapted from: Chin K et al (2004)]. 
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2.3 Predisposing genes 
 
It is known that a portion of breast cancers are associated with genetic 
susceptibility. Some genes have already been identified, conferring an increased risk of 
developing this malignancy [Table 1.5]. As previously said, hereditary breast cancer 
constitutes only about 5−10% of total breast cancers, but the genes known to be 
involved in familial breast cancer (BRCA1, BRCA2 and others), account for only about 
15-20% of the familial risk [Figure 1.13]. On the other hand, most of the genetic variants 
that contribute to the risk of developing sporadic breast cancer are unknown, and 
recent studies suggest that much of the remaining variation in genetic risk, is probably 
caused by combinations of more common, lower penetrance, genetic variants [66] and 
their interaction with environmental agents [69]. 
 
 
Figure 1.12 - Multistep model of breast cancer carcinogenesis [adapted from: Beckmann et al 
(1997)]. 
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2.3.1 High penetrance breast cancer susceptibility genes: 
 
BRCA1 and BRCA2 are two large tumor suppressor genes, with 24 and 27 
exons, respectively, found in families with breast/ovarian cancer at early onset and 
inherited in an autosomal dominant pattern. Since their identification, several high risk 
mutations have been found that can originate hereditary breast-ovarian cancer 
syndrome [70]. 
 
BRCA1 - This gene has been implicated in DNA repair, cell-cycle regulation, 
transcriptional regulation and chromatin remodeling [4]. Tumors with BRCA1 mutations 
are often triple negative and a high proportion show a "basal" aggressive phenotype 
that is associated with invasive ductal carcinomas (74%) [71] with a higher frequency of 
lung and brain metastases [72]. As previously said, BRCA1 mutations confer a lifetime 
risk for developing breast cancer of 60% to 80% and by the age of 40, the risk for 
developing ovarian cancer is 17%, increasing to 39% by the age of 70, and to 54% by 
the age of 80 [73]. 
 
BRCA2 - Mutations in BRCA2 are frequently found in families with high 
frequencies of male breast cancer [71]. It has been implicated in DNA recombination 
and repair with a role in the regulation of RAD51 activity [4]. The most frequent 
histological type of tumors with BRCA2 alterations is also invasive ductal carcinoma 
(76%) [74], related to the luminal type, with expression of ER and more frequently 
Figure 1.13 - Pie chart representing breast cancer distribution [adapted from: www.breastcare.com]. 
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metastases to the bone and soft tissues [72]. Mutations in this gene confer a lifetime 
risk for developing breast cancer of 45% up to 80% [71]. 
 
These two genes form complexes that activate the repair of double strand breaks 
(DSBs) and initiate homologous recombination [Figure 1.14]. RAD51 is the key 
component of this mechanism. Cells defective in BRCA1/BRCA2 (BRCAs) are 
hypersensitive for agents that produce DSBs. Overall, 3,492 distinct mutations, 
polymorphisms and variants were found in the BRCAs, most of them being predicted to 
truncate the protein, and some of them being population specific [74]. Women with 
BRCAs mutations can manage the risk by surveillance, prophylactic surgery and 
chemoprevention [75]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Some referral criteria for BRCA1/2 testing include: three breast cancer cases in 
first degree relatives (or second if from paternal side) from the same side of the family, 
with at least one diagnosed before the age of 50 years; or two breast cancer cases at 
Figure 1.14 - Molecular mechanism of homologous recombination [adapted from: Yata & Esashi 
(2008)]. 
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any age, if there is a case with ovarian cancer; or one breast cancer diagnosed before 
the age of 45 years and one ovarian cancer at any age [76]. 
 
TP53 - Tumor suppressor gene encoding p53. p53 acts as a transcription factor, 
involved in the control of cell cycle progression, repair of DNA damage, genomic 
stability and apoptosis [77]. This gene is constitutionally mutated in the Li-Fraumeni 
syndrome (autosomal dominant predisposition to breast cancer among others) [78]. It is 
more commonly altered somatically in BRCA1 and BRCA2 related breast cancers [79]. 
Most mutations are point mutations [80]. 
 
2.3.2 Moderate to low penetrance breast cancer susceptibility genes: 
 
Mutations in known high penetrance breast cancer susceptibility genes, account 
for only a portion of the familial aggregation of the disease. Linkage studies suggest 
that the remaining breast cancer susceptibility can be polygenic and a relative large 
number of moderate to low penetrance genes can be involved [66] [Table 1.5]. 
 
ATM - Ataxia teleangiectasia mutated gene encodes a checkpoint kinase that 
plays a role in DNA repair. Biallelic mutations in this gene are linked to the rare human 
autosomal recessive disorder called ataxia teleangiectasia [81]. Carriers have a 2 to 5-
fold risk of breast cancer [82]. 
 
CDH1 - Gene encoding E-cadherin, a calcium dependent cell adhesion 
glycoprotein, important for cell-to-cell adhesion [83]. Mutations in this gene lead to 
familial diffuse gastric cancer (autosomal dominant) and a predisposition to lobular 
breast cancer, with a risk of 50% [84]. 
 
PTEN - It is a tumor suppressor gene that encodes the protein 
phosphatidylinositol phosphate phosphatase with multiple roles in cellular regulation 
[85]. Germline mutations can lead to Cowden syndrome (autosomal dominant), 
characterized by a high risk of breast cancer, among others [86]. 
 
STK11 - This gene encodes a serine/theronine kinase and functions through 
inhibition of the mTOR pathway. It is mutated in the autosomal dominant condition 
Peutz-Jeghers syndrome, with a 30-50% risk of developing breast cancer [87]. 
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PALB2/FANCN - Encodes a protein that interacts with BRCA2 in homologous 
recombination and double-strand break repair. Biallelic PALB2 mutations are 
responsible for a subset of Fanconi anemia cases, characterized by a phenotype 
similar to that caused by biallelic BRCA2 mutations [88]. 
 
 
 
 
 
 
 
 
 
Gene involved Cytoband 
    Breast 
cancer 
risk 
Syndrome 
BRCA1 17q21 High 
Hereditary breast cancer and ovarian 
syndrome 
BRCA2 13q12.3 High 
Hereditary breast cancer and ovarian 
syndrome 
TP53 17p13.1 High Li-Fraumeni syndrome 
ATM 11q22.3 Intermediate Ataxia teleangiectasia 
CDH1 16q22.1 Intermediate 
Familial diffuse gastric cancer 
syndrome 
PTEN 10q23.31 Intermediate Cowden syndrome 
STK1 19p13.3 Intermediate Peutz-Jeghers syndrome 
NBS1 8q21 Intermediate Njimegen breakage syndrome 
BRIP/FANCJ 17q22 Intermediate Fanconi anemia 
PALB2/FANCN 16p12 Intermediate 
Lynch syndrome 
FANCA 16q24.3 Low 
FANCE 6p22-p21 Low 
MSH2 2p22-p21 Low 
MSH3 5q11-q12 Low 
MSH6 2p16 Low 
MLH1 3p21.3 Low 
PMS1 2q31-q33 Low 
PMS2 7p22 Low 
Table 1.5 - List of the main susceptibility genes for breast cancer development and syndromes 
associated [adapted from: van der Groep et al (2011)]. 
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2.4 Genetic polymorphisms  
 
The search for other genetic markers that confer susceptibility to breast cancer 
development, has led to an increase in epidemiological studies of relatively common 
genetic polymorphisms that may have a role in the metabolism of estrogen or in the 
activation or detoxification of environmental carcinogens [89].  
Genes involved in the metabolism of sex hormones are strong candidates for 
breast cancer susceptibility genes. Those in the sex hormones biosynthesis pathway 
(CYP17, CYP19 and 17 B-hydroxysteroid dehydrogenase type2) may affect production 
of, and thus exposure to, the most active estrogen, estradiol. As some of the proteins 
involved in this pathway are regulated through specific receptor binding, steroid 
hormone receptor genes, such as ER, PR and AR, are also good candidates for breast 
cancer susceptibility [90] [Table 1.6]. 
Several enzymes have evolved for the detoxification of xenobiotic compounds 
and their gene expression is induced in response to the presence of that compound. 
The action of phase I (CYP1A1 and CYP2D6) and phase II (GSTM1 and GSTT1) 
enzymes make susceptible compounds more soluble and more easily excreted, 
reducing breast cancer risk [90]. Phase I enzymes are induced by, and act on, 
carcinogens found in tobacco smoke [91], phase II enzymes, detoxify carcinogens and 
their reactive intermediates [92], and N-acetyl transferases participate in the 
detoxification of components in tobacco smoke and in cooked meat, among others [93]. 
Polymorphisms in common alleles of high penetrance genes like TP53 and 
BRCA1 that results in decreased protein activity, are associated with high lifetime risk 
of breast and other cancers [94]. 
 
25 
 
 
 
  
2.5 Epigenetics 
 
During the past decade, the somatic mutation theory of cancer has been 
changed because it became evident that epigenetic malfunctions, play an equally 
important role as genetics in cancer development. Epigenetic mechanisms coordinate 
important biological processes like X-chromosome inactivation, genomic imprinting, 
position effect variation, reprogramming of genomes during differentiation and 
development among others [95]. 
DNA hypomethylation is evident in breast cancer, with up to 50% of cases 
showing reduced 5-methylcytosine content, compared with normal tissue. 
Hypomethylation in breast carcinomas affects mainly repetitive sequences, which are 
normally heavily methylated (for instance retrotransposons), contributing to genomic 
instability [96], but it can also affect individual genes. Besides, de novo gene 
Table 1.6 - Genetic polymorphisms and their relation with breast cancer risk [adapted from: 
Dunning et al (1999)]. 
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methylation can also occur, which has been shown to be a non-random process, 
specific of different cancer types and affecting genes like BRCA and other tumor 
suppressor genes, steroid receptor genes and cell cycle-related genes [97]. DNA 
methyltransferases (DNMTs) are known to be overexpressed in various types of 
tumors, including breast cancer. Approximately 30% of patients, revealed 
overexpression of DNMT3B in tumor tissue, 5% overexpressed DNMT1 and 3% 
DNMT3A. Indeed, several polymorphisms were detected in the DNMT3B gene 
promoter and were associated with an increased risk of developing breast cancer [98]. 
miRNAs are globally downregulated in several cancers including the breast type. A 
panel of 15 miRNAs was reported to be able to distinguish between breast cancer and 
normal breast tissue, besides its ability to correlate with clinicopathological features. 
This deregulation can be due to aberrant DNA methylation or copy number variations 
[99]. As epigenetic changes are potentially reversible, the use of DNMT inhibitors and 
histone diacetylase (HDAC) inhibitors is a possible therapeutic strategy that is being 
explored [95]. 
 
 
3. The HOXB13 gene and breast cancer 
 
3.1 HOXB13 
 
Homeobox (HOX) genes are crucial regulators of cell growth and differentiation. 
These genes initiate and control gene expression cascades, that drive development. 
They encode transcription factors that function to establish basic body pattern, during 
embryogenesis and maintain the function of specific organs in the adult, providing 
intercellular information for the determination of identity, lineage and fate of the cells 
[100]. The absent or aberrant expression of tissue-specific HOX genes has been 
implicated in cancer development [101]. 
Vertebrates HOX genes are clustered in four unlinked complexes in the genome 
(the HOXA, B, C and D clusters) with 39 members [100]. They arose from an ancestral 
complex amplification of some paralogs, followed by large-scale duplications, and each 
cluster has maintained a different subset of 13 paralogs. Genes located at the 3’ ends 
of the complexes (paralog groups 1 and 2) are expressed at anterior positions within 
the hindbrain, while genes at the 5’ positions (paralog groups 9-13) are expressed in 
progressively more posterior regions in the main body axis [102] [Figure 1.15]. 
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HOXB13 maps to chromosome 17q21 and it is a paralog of the HOX13 gene, 
being the most 5’ member of the HOXB cluster and the last HOX gene to be identified 
[102]. It consists of exon 1, with 601bp, and exon 2 with 254bp, divided by one intron of 
949bp. The 5' UTR region contains 585bp and the 3' UTR region 2.027bp [103]. Its 
expression is highly specific of the tail bud and posterior domains: the spinal cord, 
digestive tract and urogenital system [102]. More recently, deregulated expression of 
HOXB13 has been associated with aggressive cancer [104]. Changes in HOXB13 gene 
expression, have been documented in small-cell lung cancer, breast cancer, prostate 
cancer, colorectal cancer, esophageal cancer and kidney cancer [105]. 
 
3.2 HOXB13 and breast cancer 
 
The expression of HOXB13 is known to be upregulated in breast cancer cells, 
compared with normal breast epithelium, suggesting a possible oncogenic role [106]. It 
has also been shown that HOXB13 is an estrogen regulated gene, negatively 
correlated to estrogen receptor (ER) status and its expression is positively correlated 
with HER2 status in ER positive but not in ER negative tumors [107]. However, a subset 
of normal breast specimens demonstrated expression of HOXB13, in the terminal duct 
lobular unit, raising the possibility that it may play a role in normal mammary 
physiology. Cells expressing HOXB13 displayed distinct morphological changes, 
characterized by a reduction in epithelial-type junctions [108].  
Observations suggest that HOXB13 may regulate a pathway that functions 
synergistically with EGF-dependent signaling, to stimulate cell motility and invasion in 
vitro, supporting the idea that it may directly contribute to tumor invasion and 
metastasis. Functional cooperation between HOXB13 and EGFR signaling pathways 
may be relevant in the context of tamoxifen resistance, since activation of growth factor 
Figure 1.15 - Schematic 
representation of the 
genomic organization of the 
mammalian HOX clusters 
and their embryonic 
expression pattern [adapted 
from: Daftang and Taylor 
(2006)]. 
28 
 
signaling pathways can cause tamoxifen-resistant tumor growth [109]. HOXB13 may 
also have a direct effect on ER signaling, since homeobox proteins have been shown 
to inhibit the histone acetyltrasferase activity of CBP/p300, a key coactivator of ER-
dependent transcriptional regulation [110]. Interestingly, the gene encoding HER2 also 
maps to this chromosomal location (17q), which raises the question about possible 
coamplification of this two genes [111]. 
HOXB13 has been shown to be also a susceptibility gene for other types of 
cancer, namely prostate cancer, in which the mutation p.Gly84Glu was described to 
increase the risk of having cancer [112]. Although there are no confirmed mutations in 
HOXB13 in breast cancer cases, some studies report that the p.Gly84Glu mutation, 
found in prostate, also increases the risk in familial breast cancers [113], while others 
claim that this association is not valid [114]. 
 
3.3 HOXB13 and tamoxifen resistance 
 
Several recent studies aimed to discover novel biomarkers and gene profiles for 
predicting risk of recurrence and response to endocrine therapy of breast cancer. With 
the development of reliable genetic markers for this purpose, it would be possible at an 
early stage, to predict which patients would benefit from alternative hormonal therapies 
[111]. 
Tamoxifen is the antiestrogen agent most prescribed in women, with both early 
stage and metastatic hormone receptor positive breast cancer [115]. As previously 
shown, tamoxifen is thought to act as a competitive inhibitor of estrogen binding to its 
receptor, with no effect on tumor cells lacking ER expression [116]. Prognosis has been 
based on clinical and pathologic parameters, however a subset of patients fail to 
respond or develop early resistance to tamoxifen (25% of ER+/PR+ tumors, 66% of 
ER+/PR- cases and 55% of ER-/PR+ cases), through diverse mechanisms [117]. 
Patients with tumors expressing high levels of HOXB13 are more likely to be 
unresponsive to the therapy [Figure 1.16], suggesting that this gene is somehow 
involved in tamoxifen resistance [111]. A recent study by Shah et al (2013) [118], actually 
concluded that HOXB13 promotes tamoxifen resistance, directly downregulating the 
expression of ERα and driving tumor proliferation by inducing expression of IL6, 
leading to independent ER growth, by activation of alternative AKT and mTOR 
pathways. 
The use of alternative hormonal therapies in such patients, such as the 
aromatase inhibitors, rapamycin, chemotherapeutic agents or inhibitors of other 
signaling pathways, may improve clinical outcome [103]. 
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3.4 HOXB13/IL17BR index and clinical outcome 
 
To discover novel biomarkers, predicting tamoxifen response, in the adjuvant 
setting, Ma and colleagues (2004) [108] conducted a microarray-based survey of gene 
expression patterns, that correlate with clinical outcome. Three genes were identified, 
HOXB13, IL17BR (interleukin 17 receptor B; induces the production of pro-
inflammatory cytokines) and CHDH (choline dehydrogenase, an enzyme that belongs 
to the family of oxidoreductases), which were significantly associated with clinical 
outcome. They hypothesized that a two-gene expression index (HOXB13/IL17BR) 
might be a novel biomarker, for predicting treatment outcome in tamoxifen 
monotherapy [Figure 1.17]. They concluded that higher expression of HOXB13 and 
lower expression of IL17BR or CHDH and a higher HOXB13/IL17BR index were 
associated with a higher risk of relapse and correlated significantly with prediction of 
poor prognosis (HER2 amplification, S-phase fraction and number of positive lymph 
nodes). HOXB13/IL17BR was reported as a much better predictor in lymph node-
negative patients than in lymph node-positive patients and, surprisingly, these genes 
predicted relapse in untreated cases. 
 
 
 
 
Figure 1.16 - Cumulative survival for patients with ER-positive tumors and with low or high levels 
of HOXB13 [adapted from: Jerevall et al (2010)]. 
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Because ER functions to suppress HOXB13 and increase IL17BR expression, 
either directly or indirectly, hormone responsive tumors should have a low index. When 
estrogen signaling is impaired by either loss of ER, aberrant expression of certain 
cofactors, or by HER2 signaling, suppression of HOXB13 and induction of IL17BR 
expression is lost, resulting in a high index [107]. 
Ma et al [119] also concluded, in another study, that HOXB13 was overexpressed 
in tamoxifen recurrence cases, whereas IL17BR was overexpressed in tamoxifen 
nonrecurrence cases, and that the two gene ratio had a stronger correlation with 
treatment outcome than either gene alone. The reduction of the tamoxifen response 
signature to two genes, raised the possibility that these genes may not only be markers 
of clinical outcome, but may be involved in breast tumorigenesis. 
Among ER-positive, lymph node-negative patients not treated with adjuvant 
chemotherapy, a molecular grade index (MGI) of five gene (BUB1B, CENPA, NEK2, 
RACGAP1, RRM2) and the HOXB13:IL17BR (H:I) index shown to be associated with 
risk of breast cancer death [120].  
In a recent study, Sgroi et al [121] concluded, through an analysis of previous 
trials, that patients with primary tumors with a high H/I index, who are disease-free after 
4.5 to 6 years of adjuvant tamoxifen therapy, receive benefit from extended adjuvant 
letrozole therapy, reducing the relative and absolute risk of recurrence at 5 years by 
67% and 16.5%, respectively.  
 
 
3.5 Epigenetic repression of HOXB13 in breast cancer 
 
Genetic analysis found that increased promoter CpG islands methylation of 
HOXB13, correlate with the decreased expression of its transcript in breast cancer ER-
Figure 1.17 - Survival probability with low or high 
HOXB13/IL17BR ratio [adapted from: Ma et al 
(2004)]. 
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positive cell lines. This aberrant epigenetic event, is associated with shorter disease 
free survival in a subset of patients. Transcriptional silencing of this gene can be 
reversed by a demethylation treatment, showing a prognostic value [122]. Because of 
this controversial results comparing with the studies about HOXB13 and 
HOXB13/IL17BR index, the author of this epigenetic study suggests that this findings 
must be interpreted separately, as only an epigenetic marker and attributes a dual role 
of this gene in breast tumorigenesis. On one hand, the expression of HOXB13 can be 
enhanced in ER-positive tumors exposed to tamoxifen treatment and, on the other 
hand, HOXB13 may undergo epigenetic silencing by hypermethylation, triggered by 
estrogen signaling in other ER-positive tumors and being probably a later event in 
tumor progression [122]. 
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  II. Aims of the study 
 
 
The main goal of this study was to clarify the role of HOXB13 in breast cancer 
development. For that purpose, the specific aims were: 
 
 Search for germline alterations in HOXB13 in familial breast cancer cases 
(including some also with prostate cancer) that have been tested, negative for the 
BRCA1/2 genes.   
 
 Determine the levels of HOXB13 expression in a series of breast carcinomas, 
with and without 17q21 gain, previously determined by CGH.  
 
 Evaluate if HOXB13 gene amplification is a major driver of upregulation of this 
gene, in breast carcinomas.  
 
 Test if there are clinico-pathological associations with HOXB13 overexpression 
in breast cancer patients. 
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  III. Experimental methodology 
 
 
1. Germline mutation analysis  
 
1.1 Samples 
 
         The selected DNA samples were extracted from blood of 100 patients with breast 
cancer at the Portuguese Oncology Institute of Porto, between 1990 and 2008. After an 
initial medical consultation, these patients with family history of breast cancer, some of 
which also had relatives affected with prostate cancer, were shown to have the referral 
criteria for BRCA1/2 mutation analysis, but had a negative genetic test. 
 
 
1.2 DNA extraction from peripheral blood 
 
1.2.1 Isolation of nucleated cells 
 
         The samples were collected in sterile tubes containing EDTA and conserved at 
4ºC or -80ºC for storage. A hypotonic solution was added (AKE: 155mM NH4Cl; 10mM 
KHCO3; 0.1mM EDTA; pH=7.4) to 3-5ml of blood in a proportion of 9-10 times that 
volume, followed by an incubation period of 30 minutes at 4ºC. The tubes were then 
centrifuged at 800g for 10 minutes. The supernatant was discarded and the procedure 
repeated until there was no significant hemoglobin in the pellet. Finally, those pellets 
were transferred to 1.5ml tubes and AKE was once again added, followed by a 
centrifugation at 3.200g for 5 minutes. The supernatant was rejected and the sample 
was stored at -80ºC until extraction. 
 
1.2.2 DNA extraction 
 
The DNA isolation was done by the salting out/chloroform protocol (Mullenbach, 
Lagoda et al 1989). Briefly, 400μl of SE buffer (6M NaCl; 0.5M EDTA; pH=8) and 400μl 
of 10% SDS  were added to the previously precipitated nucleated cells. This mixture 
was well agitated in a vortex and 40μl of proteinase K (20mg/ml) [GIBCO BRL, California, 
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USA] were added for digestion to occur in an overnight incubation at 56ºC. The next 
day, 1ml of 6M NaCl was added and the samples were incubated for 10 minutes at 
56ºC again. Then, 1ml of chloroform was added to the tubes and those were agitated 
for 30 minutes at room temperature. Samples were centrifuged at 2.000g at 4ºC for 10 
minutes and the supernatant was collected and precipitated with a volume of 
isopropanol [Merck, USA]. The resulting DNA was washed with ethanol 70% (v/v) [Merck] 
two times, and finally eluted in bidestilled water. The DNA concentration and possible 
protein contamination of the samples was measured by NanoDrop ND-1000 
spectrophotometer [NanoDrop Technologies, USA]. 
 
1.3 Polymerase chain reaction (PCR)  
 
PCR was performed on the samples to amplify the HOXB13 region in the DNA. 
Primers were designed using Primer-BLAST from NCBI database [123] [Table 3.1] and 
acquired from Thermo Scientific  [Massachusetts, USA]. 
The PCR reaction was made in a 30μl volume, adding 1X of Taq Reaction Buffer 
containing 75mM Tris-HCL, 20mM (NH4)2SO4 [Thermo Scientific], 2,5mM MgCl2 [Thermo 
Scientific], 10μM dNTP's [Applied Biosystems, California, USA], 0.5M of primer forward and 
0.5M of primer reverse, 1.5U of Taq DNA Polimerase [Thermo Scientific], 100 to 300ng of 
DNA sample, completing the final volume with ddH2O. The touchdown PCR reaction 
was carried out in the Verity thermocycler [Applied Biosystems,California,USA] with the 
following program: 97ºC during 10 minutes; 6 cycles consisting in 1 minute of 
denaturation at 97ºC, 1 minute of annealing at 64ºC and 2 minutes of extension at 
72ºC; 6 cycles consisting in 1 minute of denaturation at 97ºC, 30 seconds of annealing 
at 62ºC and 2 minutes of extension at 72ºC; 6 cycles consisting in 1 minute of 
denaturation at 97ºC, 30 seconds of annealing at 60ºC and 2 minutes of extension at 
72ºC; 22 cycles consisting in 1 minute of denaturation at 97ºC, 30 seconds of 
annealing at 56ºC and 2 minutes of extension at 72ºC; finalizing with 10 minutes at 
72ºC. The final products were analyzed using a 2% (w/v) agarose [Lonza, Basel, 
Switzerland] gel stained with 5μl of ethidium bromide (5μg/μl) [Sigma, Missouri, USA]. 
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1.4 DNA sequencing 
 
         DNA  sequencing began with a first enzymatic purification (ExoSAP) of the PCR 
product to remove the excess of nucleotides, primers or other components of the 
previous reaction. The enzymes Exonuclease I 20U/μl [Thermo Scientific] and FastAP 
Thermosensitive Alkaline Phosphatase 1U/μl [Thermo Scientific] were mixed in the ratio of 
1:2, respectively, and 1µl of this mix was added to 10µl of the amplified product. The 
reaction took place at 37ºC for 30 minutes fallowed by enzymatic inactivation 15 
minutes at 85ºC.  
Then, a new PCR was done using the BigDyeTM Terminator v3.1 Cycle 
Sequencing Reaction Kit [Applied Biosystems]. The sequencing reaction was performed in 
a 10μl volume adding 1μl of Terminator Ready Reaction Mix (with dNTP's, ddNTP's-
fluorocromes, MgCl2 and Tris-HCl buffer), 1.9μl of 5X sequencing buffer, 3.5M of 
primer forward, 1μl of ExoSAP purified product and ddH2O until reaching the required 
volume. The PCR reaction was carried out in the Verity thermocycler with the following 
program: 96ºC during 10 minutes and 35 cycles consisting in 10 seconds of 
denaturation at 96ºC, 5 seconds of annealing at 52ºC and 6 minutes of extension at 
60ºC. 
The final product was again purified, this time with Illustra Sephadex® G-50 Fine 
DNA Grade [GE Healthcare Life Sciences, Ohio, USA] columns. Briefly, Sephadex® and 
ddH2O filled the 96 wells of a plate provided by the manufacturer, and was centrifuged 
at 3900g for 4 minutes. The flow-through was discarded and 12μl of each sample were 
added to the resin and purified through it with other centrifugation at 3900g for 4 
minutes. To stabilize the single strand DNA and elute the samples, 12μl of deionized 
formamide [Applied Biosystems] were added to each samples that was then sequenced by 
 Exon 1 Exon 2 
Primer 
forward 
5'-GACGGCCGTGCTGAGCGAAT-3' 5'-GGACCCACAACCCCAGGCTCA-3' 
Primer 
reverse 
5'-AGGCCTGGGTCTGCATGGGT-3' 5'-GCCTGGGCTTGGCAGGTTCC-3' 
Table 3.1 - Primers used for polymerase chain reaction and sequencing.  
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capillary electrophoresis [Figure 3.1] in the 3500 Genetic Analysis automatic sequencer 
[Applied Biosystems].  
The electropherograms were analyzed by the Sequencing Analysis Software v5.2 
[Applied Biosystems] and the Mutation Surveyor DNA Variant Analysis Software 
[Softgenetics, Pennsylvania, USA]. 
 
 
 
 
 
  
Figure 3.1 - Schematic representation of DNA sequencing molecular principles. (a) The incorporation 
of ddNTPs truncates the DNA new chain in certain locations, during primer elongation. (b) Each ddNTP is 
labeled with a different fluorescent molecule. (c) In a sequencing machine, the fragments suffer 
electrophoresis and the different fluorescences are registered [adapted from: Ladish et al (1990)]. 
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2. HOXB13 quantitative expression analysis 
         
2.1 Samples 
 
          For this purpose, 84 samples collected from patients with breast cancer at the 
Portuguese Oncology Institute of Porto, between 1999 and 2001, were available. All 
tissue fragments had been fresh-frozen and the equivalent paraffin-embedded sections 
were stained with hematoxylin-eosin and examined by a pathologist to determine the 
diagnosis and evaluate the histopathological features. 
Within the context of a previous study done in this research center, comparative 
genomic hybridization (CGH) was performed on those samples, to find possibly 
relevant genetic gains and losses. Since HOXB13 localizes in the 17q21 chromosome 
region, for this study we have chosen all the cases with 17q21 gain (28 cases) and 56 
cases without 17q21 gain [Table 3.2].    
 
 
 
 
 
 
 With 17q gain (%) Without 17q gain (%) 
 
Number of patients 
 
28 
 
56 
Mean age (at diagnosis) 56 62 
Receptor status:   
           HER2+ 14 (50) 5 (9) 
           ER+ 19 (68) 41 (73) 
           PR+ 13 (46) 38 (68) 
Grade:   
            I 0 (0) 8 (14) 
            II 11 (39) 29 (52) 
            III 16 (57) 19 (34) 
Table 3.2 - Clinical characterization of the samples from patients with breast cancer used in this 
study, according to the 17q21 gain status. 
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2.2 RNA extraction 
 
        The piece of tumor was macerated in Petri plates with a scalpel and then 
transferred to matrix lysing tubes [MP Biomedicals, California, USA] with 1ml of TRIzol. They 
were agitated in Savant FastPrep  FP 120 Cell Disruptor [MP Biomedicals] at 6.5m/s for 
45 seconds, followed by a resting period to cool down in ice for a couple of minutes. 
The samples with TRIzol were transferred to 1.5ml tubes and 200μl of chloroform were 
mixed, then they were agitated in a vortex and centrifuged for 15 minutes at 12.000g at 
4ºC. The resulting RNA phase was separated for different tubes, 500μl of isopropanol 
[Merck] were added and the tubes were agitated and incubated at room temperature 10 
minutes for precipitation to occur. A centrifugation was done at 12.000g for 10 minutes 
as well, and the supernatant rejected. 1ml of ethanol 75% (v/v) was added to wash the 
pellet and waited 10 minutes, then centrifuged for 5 minutes at 7500g. The ethanol was 
rejected and the wash and centrifugation procedures were repeated. The ethanol was 
rejected again and the tubes were left to dry for 30 minutes at room temperature. 
Finally, RNAs were eluted in a volume of nuclease free water according to the pellet 
size (60 to 180μl) and were left to rest on ice for 20 minutes. The evaluation of RNA 
concentration was assessed using NanoDrop ND-1000 spectrophotometer. RNA was 
stored at -80ºC. 
 
 
2.3 cDNA synthesis 
 
          The cDNA synthesis was performed following the Transplex Whole 
Transcriptome Amplification (WTA) kit [Rubicon Genomics, Michigan, USA] protocol. Briefly, 
to 300ng of template RNA, 2.5μl of WTA Library Synthesis buffer and 2.5μl of WTA 
Library Stabilization Solution were added and mixed for a final volume of 24μl. The 
samples were denatured in the thermocycler for 5 minutes at 70ºC and chilled on ice 
for 2 minutes. Afterwards, 1μl of WTA Library Synthesis enzyme was added, and mixed 
samples were placed back at the thermocycler for cDNA synthesis, using the following 
program: 15 minutes at 24ºC, 2 hours at 42ºC and 5 minutes at 95 ºC, and were chilled 
immediately on ice when finished. 
For amplification, each reaction contained 7,5μl of WTA Amplification Master Mix, 
1,5μl of dNTP Mix, 5U of TITANIUM Taq DNA polymerase (5U/ μl) and 5μl of Library 
Synthesis product and nuclease free water to perform a final volume of 75μl. The tubes 
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were placed in the thermocycler and the following program was performed: 3 minutes 
at 95ºC, and 17 cycles of 20 seconds at 94ºC and 5 minutes at 65ºC. 
The cDNA was purified using the QIAquick PCR Purification Kit [QIAGEN, California, 
USA] according to the manufacturer´s protocol. Briefly, 350μl of Buffer PB were added 
to the PCR product, and this solution was transferred to a QIAquick column placed in a 
2ml collection tube. The flow through was rejected after a centrifugation at 17.900g for 
60 seconds and the column was placed again in the tube. To wash the sample, 750μl 
of Buffer PE were added to the column, followed by two centrifugations at 17.900g for 
60 seconds. The flow through was discarded after each centrifugation and the columns 
were placed in 1.5ml tubes. The cDNA was eluted with 50μl of nuclease free water and 
a centrifugation at 17.900g for 60 seconds was performed. This procedure was 
repeated to reach a final volume of 100μl and the purified cDNA was stored at -80ºC. 
 
 
2.4 Quantitative reverse-transcriptase PCR  
 
          The reactions were performed using TaqMan gene expression assays [Figure 
3.2] for HOXB13 (Hs00197189_m1) and the endogenous control assays for GUSB 
(Hs00939627_m1), from Applied Biosystems. 
The reaction was done in 96-well plates in a 7500 Real-Time PCR System 
[Applied Biosystems]. In each well were added 2μl of the previously synthesized cDNA 
(15μg/μl), 10μl of SensiFast Probe Lo-Rox mix (2x) [Bioline, London, UK], 1μl of Taqman 
HOXB13 expression assay and 7μl of bidestilled water for a total volume of 20μl. PCR 
conditions were the ones predefined by the manufacturer: 50ºC for 2 minutes, 95ºC for 
1 minute and 45 cycles at 95ºC for 15 seconds and 60ºC for 1 minute. cDNA samples 
were run in duplicate. cDNA from LNCaP prostate cell line was used to prepare four 
consecutive dilutions (dilution factor: 10X) that were used as standards, run in triplicate 
on each plate, allowing the construction of a standard curve to evaluate amplification 
efficiency. Water blanks were also added in duplicate for each gene. 
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The results were analyzed using the 7500 Software v2.0.6 [Applied Biosystems]. The 
standard curves slopes for each gene did not vary more than 0.05 and the efficiency 
was between 90% and 98% per plate. The mean quantity of HOXB13 transcripts was 
normalized for the mean quantity of the endogenous control GUSB, applying the 
comparative Ct method [124]. 
The statistical analysis and respective significance was calculated using the 
SPSS v.16 program [IBM Software, USA] and also GraphPad Prism 5 [California, USA]. 
Results were considered significantly different when p < 0.05. 
 
 
 
 
 
 
 
Figure 3.2 - TaqMan biochemistry of the probe reaction. The displacement between the quencher 
and the fluorophore (reporter), originates fluorescence that is captured as the products are being 
amplified. 
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3. Fluorescent in situ hybridization (FISH) 
 
3.1 Samples and strategy used 
 
           A series of 22 paraffin-embedded tumors was chosen for cytogenetic analysis, 
based on the levels of HOXB13 expression, determined in the previous quantitative 
expression analysis. These included 16 samples that revealed high expression of this 
gene and 6 with low expression. The 17q21 gain status was also considered [Table 
3.3].  
 
 
 
 HOXB13 high expression HOXB13 low expression 
 
17q gain: positive 
 
10 (62.5%) 
 
3 (50%) 
                 negative 6 (37.5%) 3 (50%) 
Total 16 6 
 
 
To access if there was any HOXB13 copy number gain in this series, a BAC 
clone covering the entire gene was selected (ID: 2200B24 [Invitrogen, California, USA]), 
using the University of California, Santa Cruz (UCSC) Human Genome Browser. A 
commercial probe for chromosome 17 centromeric region [Abbot Molecular] was used as 
control for ploidy. 
 
 
3.2 Isolation and amplification of plasmid DNA from E. coli 
 
          Bacteria were transferred for a 50ml Falcon with 10ml of LB culture (1% (w/v) of 
Bacto-Triptone; 0,5% (w/v) of Bacto-Yeast Extract; 0,25% (w/v) of NaCl; 100ml of 
bidestilled water) and 20μl of chloranphenicol (12.5µg/ml) to select only the resistant 
bacteria with the desired transformed plasmid. They were allowed to grow for 16 hours 
at 37ºC with orbital shaking in an agitator [ROSI 1000 Thermolyne, Iowa, USA] overnight. The 
Table 3.3  - Sample distribution according to HOXB13 levels of expression and 17q21 gain status. 
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tubes were then centrifuged at 3100g for 30 minutes and after drying for 15 minutes, 
plasmids were extracted according to the NucleoSpin Plasmid kit protocol [Macherey-
Nagel, Dϋren, Germany]. Briefly, bacteria were resuspended with A1 buffer (with RNAse), 
then the plasmid DNA was released of the cells with buffer A2 addition (by 
SDS/alkaline lysis). To neutralize the resulting lysate, buffer A3 was added and the 
unwanted cell remains were discarded after a 10 minutes 11.000g centrifugation. The 
supernatant was then transferred to NucleoSpinRPlasmid columns and a centrifugation 
of 1 minute at 11.000g was performed. Ethanolic buffer A4 was used to wash the 
column membrane and plasmid DNA was eluted with Alkaline Elution (AE) Buffer (5mM 
Tris/HCl, pH 8.5) by centrifugation at 11.000g for 1 minutes.  
DNA content was quantified using NanoDrop ND-1000 spectrophotometer and 
diluted with AE buffer [Macherey-Nagel] for a final concentration of 10ng/μl. 
For plasmid amplification the Illustra GenomiPhi V2 DNA Amplification Kit [GE 
Healthcare, UK] was used according to the manufacturer's instructions. Briefly, 9μl of 
Sample Buffer (with non-specific random primers) was added to 1μl of DNA and the 
samples were heated to 95ºC using in the thermocycler [Biometra, Gottingen, Germany] for 
denaturation during 3 minutes and then cooled at 4ºC, then, for each tube, 10μl of a 
master mix with 9μl of Reaction Buffer and 1μl of Enzyme Mix were added to gather all 
the components required for DNA amplification. The reaction was carried out in the 
thermocycler for 15 hours at 30ºC, followed by enzyme inactivation at 65ºC for 10 
minutes. 
 
3.3 Nick translation and precipitation 
 
          First, DNA content was quantified and eluted in water for a final concentration of 
1000ng/μl. For labeling the DNA with SpectrumRed [Abbott Laboratories, UK], the Nick 
translation DNA Labeling System kit was used [ENZO Life Sciences, USA] and the following 
reagents were mixed in 0,5ml ambar tubes: 1.6μl of the previous eluted DNA, 5μl of 
Reaction Buffer, 5μl of dNTP mix, 2.5μl of dTTP, 0.75mM of green fluorophore-dUTP, 
5μl of DNA Polymerase I and freshly diluted DNase I (8μl of 10X DNase I Dilution 
Buffer + 72μl of nuclease free water + 1μl of DNase I). The reaction took place in the 
thermocycler at 15ºC for 120 minutes [Figure 3.3]. At the end, 5μl of Stop Buffer were 
added and tubes were placed back in the thermocycler at 65ºC for 5 minutes. 
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For precipitation, 11μl of the labeled probe were transferred to a fresh 1.5ml tube, 
following an addition of 4μl of Human Cot-1 DNA (1mg/ml) [Life Technologies, Rockville, MD], 
1μl of bidestilled water (to a total volume of 16μl), 1.6μl of 3M sodium acetate and 40μl 
of ice-cold precipitated, dried and dissolved in hybridization buffer [Abbott Molecular] 
ethanol. The tubes were placed at -22ºC overnight and the next day were centrifuged 
at 4ºC and 15.300g for 30 minutes to create a DNA pellet. The supernatant was 
removed carefully and the tubes were left to dry in a heating plate at 45ºC for 42 
minutes, in the dark. The probe was, then, re-hydrated with 3μl of water and 7μl of 
LSI/WCP Hybridization Buffer [Abbot Molecular] and 0,5μl of SpectrumGreen Vysis 
CEP17 SGn Probe [Abbot Molecular] were added. This mix was placed in a water bath for 
30 minutes and stored at room temperature in a dark place before hybridization. 
The used probes were tested in metaphases to ensure their specificity for the 
chromosome region of interest and to evaluate the quality of the signals. 
 
3.4 Treatment and digestion 
 
            The paraffin-embedded samples were placed in the heater, at 60ºC for 10 to 30 
minutes, to melt the paraffin. Then, the slides were transferred 2 times through xylol 
(first 10 minutes, second 8 minutes) and 2 times through ethanol 100% (10 minutes 
each), and washed 3 minutes in 2xSSC. Slides were then incubated in a solution of 
0.06g/ml NaSCN [Sigma-Aldrich] at 80ºC for 10 minutes, followed by two washes, 2 
Figure 3.3 - DNase nicks the double strand DNA and E. coli DNA polymerase I removes and 
polymerizes the new chain, due to its exonuclease and polymerize activity. 
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minutes each, in 2xSSC. The slides were covered with pepsine 4mg/ml (100μl pepsine 
10mg/ml [Sigma-Aldrich], 100μl ddH20, 50μl 1M HCl) and a lamella and placed in Hybrite 
Vysis [Abbot Molecular] for 13 to 20 minutes (depending on the tumor sample) at 37ºC for 
digestion of the nucleated cells.  
 
 
3.5 Denaturation, hybridization and contrast 
 
         After digestion, the lamella was removed and the slides ware washed twice in 
2xSSC, 2 minutes each. Next, dehydration was performed through a series of alcohols: 
3 minutes in 70% alcohol, then the same time in 85% and finally 3 minutes in 100% 
alcohol. Before hybridization slides were left to dry at room temperature. Probes were 
heated for 30 minutes in a water bath at 37ºC, and 5 to 10μl were added to the slides 
that were then covered with a lamella and sealed with easy removable glue [Marabu, 
Tamm, Germany]. Slides were placed in Thermobrite StatSpin denaturation/hybridization 
system [Abbott molecular, Ilenois, USA] with the following program: 80ºC for 5 minutes (co-
denaturation) and 37ºC for 18 hours (hybridization) [Figure 3.4] .  
 
 
 
 
 
 
 
 
 
 
 
 
 
When finished, the glue and the lamella were removed and the slides were 
washed in 2xSSC/0.5% Igepal solution [Sigma-Aldrich] at 73ºC for 5 minutes and in 
2xSSC/0,1% Igepal solution for 3 minutes [Sigma-Aldrich]. Finally, the slides were 
counterstained with 10μl of 4´, 6-diamidino-2-phenylindole (DAPI) [Vector Laboratories, 
Burlingame, California, USA] were and stored at 4ºC. The observation and analysis was 
performed in a Zeiss Axioplan fluorescence microscope [Zeiss, Oberkochen, Germany] 
Figure 3.4 - Fluorescent in situ hybridization principle. The labeled probe hybridizes with the high 
complementary DNA in the desired chromosome region and the signals are then revealed by fluorescence 
microscopy. 
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coupled with a Cohu 4900 CCD camera and a CytoVision system version 3.9 [Applied 
Imaging, Santa Clara, California, USA].  
For each slide, 60 cells were counted (30 in two different regions) and for each 
cell the mean HOXB13/CEN17 ratio was calculated, by adding all the values and 
dividing by 60. 
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IV. Results 
 
 
1. HOXB13 germline mutation analysis  
 
           From the 100 DNA samples, 5 could not be amplified by PCR due to DNA 
quality and 95 were sequenced. No germline mutations were found in either the two 
exons of HOXB13, only previously described polymorphisms with the expected 
frequencies [Table 4.1]. 
 
 
 
 
2. HOXB13 mRNA expression by 17q21 status 
 
          Significant differences were observed in the transcript expression levels of 
HOXB13 between breast cancer cases with or without gain of 17q21 chromosome 
band. The Mann-Whitney non-parametric test was performed to assess the 
significance of the differences (p= 0.006) (N=84) [Figure 4.1].   
 
 
 
 
 
 
 
Ref Allele/ 
Variant Allele 
dbSNP ID Variant Type Substitution N (fr) 
A/G rs9900627 Synonymous S171S 20 (0,21) 
G/A rs8556 Synonymous S122S 24 (0,25) 
Table 4.1 - Main polymorphisms found in exon 1 and exon 2 of HOXB13 and frequencies (fr). 
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3. HOXB13 copy number changes 
 
    Among the 22 selected tumor samples, eight were found to have HOXB13 
amplification with values of HOXB13/CEP17 ratio between 2.0 and 3.0 [Table 4.2]. 
However, no statistically significant difference was found between the group of samples 
with and without HOXB13 amplification concerning the levels of expression of this gene 
(p= 0.145), although there is a visible tendency for the mean expression values to be 
higher in the group where amplification was found [Figure 4.3]. 
 
 
 
 
 
Figure 4.2 - Examples of cell images captured by fluorescence microscopy, after 
fluorescent in situ hybridization (FISH). Red signals correspond to the gene (HOXB13) and 
green signals to the chromosome 17 centromeric region (CEP17). (A) Tumor cells with normal 
copy number; (B) Tumor cells with HOXB13 amplification. 
Figure 4.1- Boxplot representing HOXB13 expression levels (logarithmic scale) in samples with 
and without 17q21 gain. 
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Samples CGH 17q21 Ratio 
87_99 no gain 1.1 
381_99 no gain 1.0 
509_00 gain 2.8 
531_99 gain 2.1 
876_01 gain 2.0 
1024_99 gain 2.5 
1048_99 no gain 1.5 
1580_01 no gain 1.1 
1951_00 gain 2.5 
2473_00 no gain 1.1 
3664_00 gain 1.6 
3868_00 gain 1.2 
5941_99 no gain 1.1 
5980_99 gain 1.1 
6406_99 gain 2.3 
7016_00 gain 3.0 
7166_00 gain 1.0 
7270_99 no gain 1.1 
7586_00 gain 1.1 
7690_00 gain 1.2 
7775_00 no gain 1.3 
7835_00 gain 2.4 
Table 4.2 - Fluorescent in situ hybridization results. HOXB13/CEP17 relative ratio and 17q21 status, 
analyzed by CGH, for each sample. Cases with HOXB13 amplification are highlighted. 
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4. HOXB13 expression by 17q21 and HOXB13 copy number 
 
When comparing the 17q21 status, defined by the CGH data previously obtained, 
and the HOXB13 gene copy number status, we can consider three groups. The first 
group that includes all the samples with HOXB13 amplification and that also presents 
17q21 gain, as expected, and the remaining two groups with the samples that showed 
no amplification, but that were separated by 17q21 status. Samples without 17q21 
gain, that were not analyzed by FISH, were considered to have no HOXB13 
amplification and were also included in the statistical test (N=70). To compare these 
three groups regarding HOXB13 levels of expression at the same time, the Kruskal-
Wallis test was performed, and a statistical significance was found (p= 0,010) [Figure 
4.4]. However, if we compare the group with 17q21 gain and no amplification of 
HOXB13 with the remaining groups, using the Mann-Whitney test, there are no 
statistical significant differences (p= 0.245; p= 0.228), which are only observed 
between the group of samples with 17q21 gain/amplification and without 17q21 gain/no 
amplification (p= 0.006). 
 
Figure 4.3 - Boxplot representing HOXB13 expression levels (logarithmic scale) in tumors with 
amplification (Ratio>2)  of this gene and tumors with no amplification (Ratio<2). 
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5. Clinico-pathological associations 
 
There were no significant associations between the levels of HOXB13 expression 
and some clinical features, namely: ER status (p= 0.395), PR status (p= 0.193), 
molecular subtyping (p= 0.114) and histological type (p= 0.762). 
 
A significant and progressive association was observed between HOXB13 levels 
of expression and tumor grade (N=83) (p=0.015) [Figure 4.5], as well as a positive 
association concerning HER2 status (N=83) (p=0.019) [Figure 4.6]. 
 
 
 
 
Figure 4.4 - Boxplot representing HOXB13 expression levels (logarithmic scale) in cases with and 
without HOXB13 amplification and with or without 17q21 gain. 
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Figure 4.5 - Boxplot representing HOXB13 expression levels (logarithmic scale) in groups with 
different tumor grades. 
Figure 4.6 - Boxplot representing HOXB13 expression levels (logarithmic scale) concerning 
ERBB2 status. 
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Considering the recurrence data until 2009, a relapse in the disease occurred in 
only 14 of the 54 patients. Although there was no statistical significant association 
between this event and the expression levels of HOXB13 transcript (p= 0.132), 
expression levels tend to be higher in cases with tumor recurrence [Figure 4.7]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding disease survival data, Kaplan-Meier survival analysis was performed 
with a total of 82 patients from the series used for qRT-PCR, with information on the 
diagnosis data and time of death (with evidence of the disease) or last appointment 
data. Forty-nine cases were considered to have low values of HOXB13 expression and 
33 to have high values (below or above median value = 1.94, respectively) [Figure 4.8]. 
Mantel-Cox test reveals no statistical significance between the survival probability of 
this two groups (p = 0.997), in fact the mean survival of patients considered to have 
expression levels of HOXB13 ≤ 1.94 was 119,130 months, while patients with 
expression levels of HOXB13  > 1.94 was 118,275 months.  
Considering only patients that were receiving tamoxifen treatment (N=59), 
Kaplan-Meier survival analysis was again performed to search for a relation between 
therapy response and HOXB13 levels of expression, but there was no difference 
(Mantel-Cox, p= 0.577) [Figure 4.9]. 
Figure 4.7 - Boxplot representing HOXB13 expression levels (logarithmic scale) in cases 
where there was recurrence and no recurrence of the disease. 
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Figure 4.8 - Disease specific survival probability representation between cases with low and high 
expression levels of HOXB13.  
Figure 4.9 - Disease specific survival probability representation, in patients that were under 
tamoxifen therapy and with high or low levels of HOXB13 expression levels. 
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   V. Discussion 
 
Breast cancer presents a challenge to prognosis and therapeutic choices due to 
its heterogeneous nature. Improving the understanding of the molecular pathways 
involved in breast cancer development is an opportunity for predicting tumor 
responsiveness to treatment as well as tumor aggressiveness [111]. The search for 
novel tumor biomarkers for breast cancer development led to some interesting, 
relatively recent, discoveries based on genome-wide microarray analysis, and HOXB13 
was one of the genes that came out as significantly associated with clinical outcome 
[104]. Furthermore, since HOXB13 was recently discovered as a prostate cancer 
susceptibility gene and men carriers of BRCA1/2 mutations have increased risk for 
prostate cancer [112], it became important to look for the role of this gene in hereditary 
predisposition to breast cancer.  
HOXB13, like many other homeobox genes, encodes a highly conserved 
transcription factor, essential in embryonic development. It presents temporal and 
spatial colinearity in the body axis and its expression should be at basal levels in breast 
tissue of developed individuals [100,102]. 
 HOXB13 in breast cancer is described as being overexpressed [106]. Its 
predictive value in estrogen receptors positive (ER+), node negative, breast cancers 
was already demonstrated by numerous studies that correlate high levels of expression 
of this gene with disease aggressiveness, poor clinical outcome and tamoxifen therapy 
failure, in many studies measured together with other gene (IL17BR) [107,108,121]. 
However, not much is known about how it contributes to disease progression and there 
are no publications at all about what is the mechanism that triggers HOXB13 
overexpression. In this study, we tried to understand if HOXB13 could be involved in 
any case of familial breast cancer (some of which also with prostate cancer cases), 
wildtype for BRCA1/2, and if copy number changes in this gene could be responsible 
for its upregulation in breast carcinomas. 
 
1. HOXB13 germline mutation analysis 
 
Little is known about germline mutations in HOXB13 in breast cancer patients. In 
this study, no deleterious germline mutations were found in the 95 samples that were 
fully sequenced. In the literature, until now, only the p.G84E mutation (rs138213197), 
first described in prostate cancer, was sought in two publications, but the results were 
contradictory. Alanee et al (2012) [112] found an association between this HOXB13 
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variant and breast cancer, with seven times higher prevalence of the p.G84E mutation 
in patients with familial breast cancer wild type for BRCA1/2, than in control cases. On 
the other hand, Akbari and colleagues (2012) [113] claim no association between this 
mutation and breast cancer risk, since in their study similar frequencies in cases with 
the disease and controls were found. Both used DNA from peripheral blood of more 
than 4.000 cases, which, in fact, contrasts with the number of cases analyzed in our 
study, although we have performed full sequencing instead of single mutation analysis. 
 
2. HOXB13 mRNA expression by 17q21 status 
 
          Since HOXB13 localizes in chromosome 17q21 [102], we evaluated whether or 
not copy number changes explained expression levels of this gene in breast 
carcinomas, by studying distinct groups of cases with and without 17q21 gain. Our 
study shows that there was statistically significant differences between the two groups 
of tumors, when we first considered only the available CGH data. One should 
remember that the CGH technique in chromosome metaphases has its intrinsic 
limitations, which includes the exclusive detection of gross and unbalanced 
abnormalities and not copy number alterations of individual genes. It is also important 
to notice that, although the series of samples used was not very large, this study was 
the first to evaluate the role of 17q21 and HOXB13 copy number changes as the 
genetic mechanism behind HOXB13 deregulation in breast cancer, with this results 
increasing the strength of this hypothesis. 
 
3. HOXB13 expression by 17q21 and HOXB13 copy number 
 
As mentioned above, the presence of 17q21 copy number gain by CGH does not 
necessarily mean that a particular gene in that band is gained or amplified. We 
therefore decided to search for amplifications of the HOXB13 gene using FISH with 
specific probes in samples with low and high values of HOXB13 expression and with or 
without gain of 17q21. With this strategy we could directly evaluate if the expression 
level our gene of interest, was indeed associated with gene copy number changes. 
Surprisingly, the eight cases with HOXB13 amplification did not show statistically 
significant higher levels of HOXB13 expression compared with those with no 
amplification, although the mean value was higher in the former. In fact, one of the 
cases considered to have low expression of our gene of interest had the highest 
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HOXB13/CEP17 amplification ratio and, on the other hand, 9 cases considered to have 
high expression of HOXB13 had low HOXB13/CEP17 ratios. Another interesting fact 
was that, when we compared the two groups with no amplification but with and without 
17q21 gain, including the 48 samples without 17q21 gain and no amplification, not 
analyzed by FISH, the values of HOXB13 expression gained statistical significance. 
These data, once again, goes in line with our first results concerning HOXB13 
expression analysis and the CGH data and with our assumptions. However, additional 
studies would be necessary to identify alternative mechanisms involved in HOXB13 
overexpression in the cases where there was no copy number gain, maybe further 
exploring mutational and epigenetic events or chromosome translocations, which are 
also mechanisms of oncogene activation. 
 
4. Clinico-pathological associations 
 
The majority of the available studies involving HOXB13 and breast cancer were 
aimed for its prognostic role and capacity of predicting tamoxifen therapy benefit, as 
already said [111,117,118]. In our study HOXB13 revealed no prognostic or predictive 
value, because we found no statistically significant differences in recurrence, disease 
survival and other clinico-pathological parameters like molecular and histological 
subtyping and ER/PR status, regarding HOXB13 expression levels. This is most likely 
due to insufficient power of our study to detect such differences, and also due to 
differences in the methodology and techniques used for diagnosis and therapy choice 
10 years ago, since most literature data in larger series support HOXB13 expression as 
having a predictive value regarding hormonal therapy.   
A study by Wang (2007) [107] describes a significant association between high 
levels of expression of HOXB13 and estrogen receptors negative (ER-) tumors, which 
goes in line with another recent study by Shah (2013) [118], clarifying that HOXB13 
directly suppresses ERα and promotes an ER independent pathway. Wang also found 
an ER dependent association with HER2 status and progesterone receptors (PR), in 
which ER+ tumors with this particular type of receptors also had higher levels of 
HOXB13 expression. The association with grade was also expected since HOXB13 is 
overexpressed mainly in tumors with a more aggressive phenotype and clinical course 
[118], a fact that was indeed observed in our study. 
Concerning disease recurrence, survival and therapy resistance, multiple 
publications [107,108,11,117,118,121] reported that primary tumors with high expression of 
HOXB13 had a significantly higher risk of disease recurrence (HR=3.55) and death 
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(HR=3.438) in treated and untreated patients with tamoxifen compared to those with 
low HOXB13 expression. A publication involving cell lines that express higher levels of 
HOXB13 reported that these type of cells, that were the ones with more aggressive 
features, grow faster and display tamoxifen resistance through estrogen independent 
proliferation [118]. It has also been described by a mechanistic investigation [118] that 
HOXB13 transcriptionally upregulates IL-6 and its mediated pathways (which act as 
mediators of disease progression) by tumoral proliferation and stromal recruitment, 
possibly increasing the risk of relapse. This information is actually important, since 
patients with this activated alternative pathways can benefit from mTOR inhibitors 
instead of tamoxifen, aimed for ER+ tumors. The same study also refers that HOXB13 
was found to be overexpressed in distant metastases from breast cancer of 
nonsurvivors compared with survivors and with normal breast organoids.  
Finally, but not less interesting, Jerevall et al (2010) proposed a possible 
coamplification of the HOXB13 gene and HER2, since he observed a positive 
association between the expression of HOXB13 and HER2 amplification, as we also 
did. This theory was however not supported by our data, because the majority of cases 
with HOXB13 amplification did not revealed HER2 amplification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  VI. Conclusions 
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Having in mind the results obtained in this study, we can conclude that: 
 
           No evidence was found that the HOXB13 gene is a significant contributor to 
inherited predisposition to familial breast cancer in Portugal, both regarding the 
recurrent G84E mutation or any other.   
           HOXB13 expression levels seem to be higher in breast carcinomas with 
HOXB13 amplification and are significantly higher in tumors with 17q21 gain and 
HOXB13 copy number gain, when compared with tumors without this gain and no 
amplification, suggesting that copy number gain can be a mechanism responsible for 
HOXB13 overexpression.            
           There is a progressive association between HOXB13 expression and tumor 
grade, as well as a significant association with HER2 status that does not seem to be 
caused by co-amplification. 
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  VII. Future Perspectives 
 
 Increase the size of the sample series for germline mutation analysis. 
 Search for somatic mutations in breast cancer samples. 
 Increase the size of the sample series for FISH analysis and include some samples 
of normal tissue in the expression analysis to verify the HOXB13 levels in normal 
tissue. 
 Quantify the levels of expression of IL17BR and compare the results of the 
HOXB13/IL17BR ratio with that of HOXB13 alone. 
 Clarify the epigenetic methylation status of this gene in normal tissue and breast 
cancer tissue. 
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